Trial Profile
A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Jan 2024
Price :
$35
*
At a glance
- Drugs Olipudase alfa (Primary)
- Indications Niemann-Pick diseases
- Focus Registrational; Therapeutic Use
- Acronyms ASCEND
- Sponsors Sanofi Genzyme
- 30 Nov 2023 Status changed from active, no longer recruiting to completed.
- 15 Nov 2023 This trial has been completed in Netherlands (Date of the global end of the trial: 19-Oct-2023), according to the European Clinical Trials Database record.
- 15 Nov 2023 This trial has been completed in Netherlands (Date of the global end of the trial: 19-Oct-2023), according to the European Clinical Trials Database record.